Segment Information

3 Months Ended

Mar. 31, 2025

Segment Information [Abstract]

SEGMENT INFORMATION

NOTE 12. SEGMENT INFORMATION

The Company has determined it operates as a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. The Company’s chief operating decision maker, its Chief Executive Officer (the “CEO”), manages the Company’s operations on a consolidated basis. The CEO assesses the segments performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment’s personnel and general and overhead costs.

In addition to the significant expense categories included within net loss presented on the Company's condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):

	Three Months Ended March 31,
	2025			2024
Personnel-related costs	$	8,431		$	5,880
General and overhead costs		3,611			3,082
Program costs
Briquilimab platform		1,957			1,438
CMO		2,138			1,133
CSU		2,746			2,135
Asthma		1,393			—
CIndU		885			425
SCID		523			404
MDS/AML		118			575
Total program costs		9,760			6,110
Total operating expense		21,802			15,072
Other income, net		561			1,344
Net loss	$	(21,241	)	$	(13,728	)

All long-lived assets are located in the United States.